Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 20 of 30
May 1, 2026The healthcare sector in April 2026 experienced a whirlwind of personnel changes that reflect broader trends in the industry’s adaptation to evolving market demands and operational challenges. This post unpacks the key developments across leading companies and organizations.
Apr 29, 2026The pharmaceutical giant Pfizer has secured a legal settlement that delays generic competition for one of its top-selling drugs until 2031. This move has important implications for the pharmaceutical industry, generic manufacturers, and patients worldwide. The settlement highlights ongoing tensions between innovator companies and generic drugmakers, regulatory landscapes influencing market dynamics, and the strategic measures companies take to protect valuable assets.
Apr 29, 2026This strategic deal marks a significant expansion in AbbVie's oncology portfolio by focusing on the challenging KRAS mutation. It reflects broader biotech industry trends toward targeted therapies for difficult-to-treat cancers and includes detailed financial structures and risk assessments.
Apr 28, 2026With the appointment of Ramin H. Garijo as the new CEO of Sanofi, the pharmaceutical giant faces the challenge of easing its dependency on Dupixent, a core revenue driver. This leadership change opens a window for strategic diversification and innovation within the company.
Apr 22, 2026After partnering in early 2021 to develop RIPK1 blockers, Eli Lilly has disengaged from its alliance with Rigel Pharmaceuticals. This move follows Lilly's earlier withdrawal from one CNS-targeted program, highlighting the complexities and hurdles faced in advancing RIPK1 inhibitors. This post explores the implications of this development for the RIPK1 field and the broader pharmaceutical landscape.
Apr 21, 2026The acquisition of Kelonia Therapeutics marks a significant milestone in Eli Lilly’s ongoing commitment to in vivo genetic medicine. This deal complements their recent strategic purchases and underscores a focused expansion into cell therapy fields such as CAR-T, aiming to bring novel treatments for multiple myeloma to clinical fruition.
Apr 18, 2026Trilliant Health's recent report reveals a dramatic 62% surge in behavioral health demand over the past several years. Despite this growth, systemic issues such as clinician shortages and accessibility challenges continue to impede care delivery, underscoring the complex landscape facing the behavioral health industry today.
Apr 15, 2026Amid an ongoing reevaluation of its business alliances, Takeda is narrowing its focus by cutting ties with Veritas In Silico, a biotech firm known for its novel mRNA-targeting small molecule drug development. This decision follows Takeda’s earlier separation from Denali Therapeutics, reflecting a continued pattern of partnership pruning intended to concentrate efforts and resources on prioritized projects and technologies.
Apr 15, 2026In recent transactions, leading biopharma companies such as Gilead, AstraZeneca, and Vertex have pursued acquisitions that emphasize the value of skilled staff and research teams. This trend marks a strategic focus on human capital as a key driver of innovation and competitive advantage in the sector.
Apr 14, 2026Pharmaceutical companies are entering the first quarter earnings reports season with anticipation focused on innovative drugs and strategic deals. Novo Nordisk will lead with revealing revenue numbers from its oral GLP-1 medication, setting the pace for discussions around approvals, pricing, and external economic pressures including new tariffs.
Apr 13, 2026In a groundbreaking clinical development, Revolution Medicines has reported unprecedented trial data indicating that its targeted daily pill for metastatic pancreatic cancer patients significantly extends survival compared to traditional chemotherapy. This advancement heralds a possible shift toward more effective oral therapies in a disease with historically poor prognoses.
Apr 13, 2026In a major development within the oncology biopharmaceutical landscape, Regeneron has formed an alliance with Telix, a company specializing in radiopharmaceuticals. The deal, potentially worth $4.3 billion, marks Regeneron's strategic entry into a cutting-edge field of targeted cancer treatment. This partnership enhances Regeneron's capabilities and complements its existing cancer portfolio with novel radiolabeled therapies.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.